secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274053
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q3 2023 cash $164.4M; CABA-201 data expected H1 2024; IND clearances for SSc and gMG
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments of $164.4M as of Sept 30, 2023, up from $106.5M at Dec 31, 2022.
- R&D expenses $13.8M (vs $8.2M in Q3 2022); G&A expenses $4.9M (vs $3.6M).
- Initial clinical data from CABA-201 Phase 1/2 trials in lupus and/or myositis expected in first half of 2024.
- IND clearances received for CABA-201 in systemic sclerosis (SSc) and generalized myasthenia gravis (gMG).
- WuXi ATU selected as GMP manufacturing partner; Oxford Biomedica as lentiviral vector supplier for CABA-201.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523274053/0001193125-23-274053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523274053/d581425d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer